Patents by Inventor Martin E M Noble

Martin E M Noble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoindolin-1-one derivatives
    Patent number: 8258175
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: September 4, 2012
    Assignee: Cancer Research Technology Limited
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Roger John Griffin, Bernard Thomas Golding, John Lunec, Martin E. M. Noble, David R. Newell, Alan H. Calvert
  • Isoindolin-1-One Derivatives
    Publication number: 20080261917
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Application
    Filed: August 26, 2005
    Publication date: October 23, 2008
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Robert John Griffin, Bernard Thomas Golding, John Lunec, Martin E.M. Noble, David R. Newell, Alan H. Calvert
  • Cyclin dependent kinase inhibitors
    Patent number: 6677345
    Abstract: A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: January 13, 2004
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury
  • Cyclin dependent kinase inhibiting purine derivatives
    Patent number: 6303618
    Abstract: Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: October 16, 2001
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding, Jane A Endicott, Martin E M Noble, Francis T Boyle, Philip J Jewsbury